HYAL4: A Potential Drug Target and Biomarker (G23553)

Target Name: HYAL4

NCBI ID: G23553

HYAL4

HYAL4: A Potential Drug Target and Biomarker

Hyal4, also known as OTTHUMP00000212009, is a protein that is expressed in various tissues of the human body, including the liver, pancreas, and blood cells. It is a member of the HYAL family, which is characterized by the presence of a hydrophobic transmembrane domain and a cytoplasmic tail. The HYAL family plays a crucial role in cell signaling and homeostasis, and the dysregulation of HYAL genes has been implicated in the development of various diseases, including cancer, diabetes, and autoimmune disorders.

Recent studies have identified HYAL4 as a potential drug target and biomarker for various diseases, including cancer. HYAL4 has been shown to be involved in a variety of cellular processes, including cell adhesion, migration, and angiogenesis. It has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues, and is a target for many diseases, including cancer.

One of the key advantages of HYAL4 as a drug target is its potential to be used in combination with other therapies. Because HYAL4 is expressed in many different tissues of the body, it can be used as a biomarker to monitor the effectiveness of different treatments. This is especially important in cancer, where accurate monitoring of the effectiveness of different therapies is critical for ensuring the best possible outcomes.

Another advantage of HYAL4 is its potential to be used as a monoclonal antibody (mAb) target. MAbs are laboratory-produced antibodies that can be used to detect and target specific proteins in the body. By using HYAL4 as a mAb target, researchers can study the effects of different therapies on the expression and activity of HYAL4, and potentially identify new biomarkers for cancer.

In addition to its potential as a drug target and biomarker, HYAL4 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of tissues. The HYAL family plays a role in the regulation of various cellular processes, including cell adhesion, migration, and angiogenesis. This regulation is critical for the development and maintenance of tissues, and is a target for many diseases, including cancer.

Overall, HYAL4 is a protein that has the potential to be a drug target and biomarker for various diseases, including cancer. Its expression and regulation in various tissues of the body make it an attractive target for researchers, and its potential as a monoclonal antibody target adds a new dimension to its potential applications. Further studies are needed to fully understand the role of HYAL4 in the development and maintenance of tissues, and to identify its potential as a drug target and biomarker.

Protein Name: Hyaluronidase 4

Functions: Endo-hyaluronidase that degrades hyaluronan to smaller oligosaccharide fragments. Has also chondroitin sulfate hydrolase activity, The best substrate being the galactosaminidic linkage in the sequence of a trisulfated tetrasaccharide

The "HYAL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HYAL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets